US biotech Eikonoklastes opens European HQ in San Sebastián, hiring from January
What's the deal? US gene-therapy biotech Eikonoklastes Therapeutics is opening its European headquarters in San Sebastián, basing it at BIC Gipuzkoa, with its first hires starting in January. Alex García-Ingrisano will lead the European arm as managing director. The initial team is expected to number about six.
What does the company do? Cincinnati-based Eikonoklastes, incorporated in 2019, develops gene therapies. Its lead candidate, ET-101, targets amyotrophic lateral sclerosis (ALS). The company plans to advance that work in Europe alongside its US programs and to build a regulatory and collaboration base on the continent.
Why San Sebastián? The city is investing in life-sciences infrastructure, anchored by BIC Gipuzkoa and the planned €80 million SOKAI hub, due to open in 2027. Eikonoklastes intends to move to the SOKAI hub in March.
Why now? The move lands in a more active ALS gene-therapy field. Amsterdam-based VectorY recently expanded funding for a Phase 1/2 trial, while InsmedDealroom has a profile for this one. Try Dealroom → began a first-in-human ALS gene-therapy study this year.
What could go wrong? The announced team of about six is modest. Its significance will hinge on clinical progress, financing, and concrete local partnerships rather than the overseas address alone.
The signal: The arrival reinforces the Basque Country as a growing life-sciences hub, drawing US biotechs seeking European regulatory footholds and research ties. Whether that translates into lasting local weight depends on what Eikonoklastes builds next.
Read more: diariovasco.com
Image credit: Generated with Gemini